ELDN Projected Dividend Yield
Eledon Pharmaceuticals Inc ( NASDAQ : ELDN )Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. Co. is developing immune-modulating therapies for the management and treatment of life-threatening conditions. Co.'s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. 20 YEAR PERFORMANCE RESULTS |
ELDN Dividend History Detail ELDN Dividend News ELDN Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |